Lawrence and Isabel Barnett Drug Development Program There is an urgent need for new and improved therapies for ALS, as there is still no cure Since 2016, the Lawrence and Isabel Barnett Drug Development Program has supported the preclinical assessment of new and repurposed ALS therapies by awarding grants worth up to $500,000 over two years
Lawrence and Isabel Barnett Drug Development Program Among other accomplishments, this milestone-based program made possible the development and clinical testing of antisense therapy against a common gene mutation in ALS, the first application of antisense therapy to any neurologic disease
Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS . . . CINCINNATI – Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular
Coave wins grant to advance gene therapy CTx-TFEB for ALS “We are proud to help drive the crucial transition from preclinical to clinical development for potential new ALS therapies through our Lawrence and Isabel Barnett Drug Development Program,” Dave said
The Lawrence and Isabel Barnett Drug Development Program These 2-year awards with a maximum budget of $500,000 are open to both industry and academic investigators Applicants should have a development candidate in hand as this funding opportunity aims to support programs that have a high probability of entering the clinic within 3 years
LLY Stock Impact Report for 11 13 2024 | News Quantified Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Thera
The Lawrence and Isabel Barnett Drug Development Program (2023) The Lawrence and Isabel Barnett Drug Development Program, named in honor of the prominent entertainment executive and television and theater actress, provides industry and academic investigators with up to $500,000 over two years to support the preclinical assessment of novel therapies or repositioned treatment approaches for ALS